US-based provider of laser and light-based aesthetic treatments Cynosure has acquired the assets of Ellman International for an estimated $13.2m.
With annual revenues of around $25m, Ellman develops advanced radiofrequency (RF) technology for precision surgical and aesthetic procedures as well as provides a line of aesthetic lasers.
Go deeper with GlobalData
The deal is expected to be accretive to Cynosure’s earnings per share by the first quarter of 2015.
According to Cynosure, RF product line of Ellman broadens its technology platform and the aesthetic lasers allow the company to provide a value solution at a different price point than the current offerings.
Cynosure chairman and chief executive officer Michael Davin said: "This transaction complements our brand portfolio, expands our market opportunities and enhances our recurring revenue stream.
See Also:
"Ellman combines a 55-year history of innovation with an outstanding reputation for developing high-quality products that serve the needs of a global customer base.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"Thousands of physicians, cosmetic surgeons and medical aestheticians rely on Ellman technology. We believe these assets are an excellent strategic fit for Cynosure."
The product line of Ellman will be used in aesthetic and multi-specialty surgical indications such as facial plastic and general surgery, gynaecology, ear, nose and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology.
The high-frequency, low-temperature RF technology of Ellman is optimised for achieving surgical precision and controlled haemostasis.
Davin said: "The efficacy of products such as Ellman’s versatile Surgitron radiowave platform technology is supported by clinical validation in more than 300 surgical publications.
"What differentiates Ellman’s platform technology is its ability to consistently achieve favourable clinical outcomes with minimal tissue damage, rapid recovery and less scarring."
Apart from Surgitron, the Ellman product line includes the RF-based Pelleve Wrinkle Reduction System for non-ablative skin rejuvenation that can be performed in an hour or less.
In February, Ellman’s PelleFirm RF Body Treatment System secured US FDA clearance for tissue heating and the temporary reduction in the appearance of cellulite.
The system is also CE Marked for body skin tightening and cellulite reduction.
